Syneos Health - SYNH Stock Forecast, Price & News

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Syneos Health Price Performance

Shares of Syneos Health stock traded down $0.58 during trading on Friday, reaching $68.88. 379,043 shares of the stock traded hands, compared to its average volume of 771,714. The company has a market capitalization of $7.07 billion, a price-to-earnings ratio of 25.89 and a beta of 1.68. The business has a fifty day simple moving average of $71.04 and a two-hundred day simple moving average of $75.85. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.10 and a quick ratio of 1.10. Syneos Health has a 52-week low of $62.28 and a 52-week high of $104.18.

Syneos Health (NASDAQ:SYNH - Get Rating) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.17. The firm had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.39 billion. Syneos Health had a return on equity of 14.04% and a net margin of 5.13%. The business's quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 earnings per share. Sell-side analysts expect that Syneos Health will post 4.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SYNH. Barclays decreased their target price on Syneos Health from $90.00 to $80.00 in a report on Wednesday, August 3rd. TheStreet lowered Syneos Health from a "b" rating to a "c+" rating in a research note on Wednesday, May 18th. William Blair lowered Syneos Health from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 3rd. Robert W. Baird cut their price target on Syneos Health to $89.00 in a research note on Tuesday, August 9th. Finally, Citigroup cut their price target on Syneos Health from $80.00 to $70.00 in a research note on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $84.67.

Insider Buying and Selling

In related news, COO Michael Lee Brooks sold 1,002 shares of Syneos Health stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $78.00, for a total value of $78,156.00. Following the completion of the transaction, the chief operating officer now owns 47,552 shares in the company, valued at $3,709,056. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Syneos Health news, CEO Michelle Keefe sold 8,333 shares of the firm's stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $72.81, for a total value of $606,725.73. Following the completion of the sale, the chief executive officer now owns 71,266 shares of the company's stock, valued at $5,188,877.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Michael Lee Brooks sold 1,002 shares of the firm's stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $78.00, for a total transaction of $78,156.00. Following the completion of the sale, the chief operating officer now directly owns 47,552 shares of the company's stock, valued at approximately $3,709,056. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,403 shares of company stock worth $1,646,313. Corporate insiders own 0.34% of the company's stock.